• 1. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Introduction to (3S)-3-amino-3-(3,5-difluorophenyl)propanoic Acid (CAS No. 1241679-50-4)

(3S)-3-amino-3-(3,5-difluorophenyl)propanoic acid, with the CAS number 1241679-50-4, is a significant compound in the field of pharmaceutical chemistry and biochemistry. This compound has garnered attention due to its unique structural properties and potential applications in drug development. The presence of a stereogenic center at the third carbon atom, along with the incorporation of fluorine atoms in the phenyl ring, contributes to its distinct chemical behavior and biological activity.

The molecular structure of (3S)-3-amino-3-(3,5-difluorophenyl)propanoic acid consists of an amino group (-NH?) and a carboxylic acid group (-COOH) attached to a propanoic acid backbone. The stereogenic center at the third carbon atom is crucial for its chiral properties, which can significantly influence its biological interactions. Additionally, the 3,5-difluorophenyl group introduces electronic and steric effects that can modulate the compound's reactivity and binding affinity to biological targets.

In recent years, there has been growing interest in the development of fluorinated compounds for their enhanced metabolic stability and improved pharmacokinetic profiles. The fluorine atoms in (3S)-3-amino-3-(3,5-difluorophenyl)propanoic acid contribute to these desirable properties by increasing lipophilicity and reducing susceptibility to enzymatic degradation. This makes the compound a valuable scaffold for designing novel therapeutic agents.

Current research in the field of medicinal chemistry has highlighted the potential of chiral amino acids as building blocks for drug discovery. The enantiomerically pure form of (3S)-3-amino-3-(3,5-difluorophenyl)propanoic acid has been explored in several preclinical studies for its ability to interact selectively with biological receptors. Such selectivity is critical for minimizing side effects and improving therapeutic efficacy.

One notable application of this compound is in the synthesis of protease inhibitors, which are essential for treating various diseases, including cancer and infectious disorders. The unique structural features of (3S)-3-amino-3-(3,5-difluorophenyl)propanoic acid allow it to mimic natural amino acids and disrupt enzyme activity by binding to specific pockets on the protease surface. This has led to the development of several promising lead compounds that are currently undergoing further investigation.

Another area where this compound has shown promise is in the treatment of neurological disorders. Studies have demonstrated that fluorinated amino acids can cross the blood-brain barrier more efficiently than their non-fluorinated counterparts. This property makes (3S)-3-amino-3-(3,5-difluorophenyl)propanoic acid an attractive candidate for developing drugs targeting central nervous system disorders such as Alzheimer's disease and Parkinson's disease.

The synthesis of (3S)-3-amino-3-(3,5-difluorophenyl)propanoic acid involves multi-step organic reactions that require careful optimization to achieve high yields and enantiomeric purity. Advanced synthetic techniques such as asymmetric hydrogenation and fluorochemical transformations have been employed to construct the desired molecular framework efficiently. These synthetic strategies not only highlight the compound's complexity but also showcase the advancements in synthetic organic chemistry that enable the production of such intricate molecules.

In conclusion, (CAS No. 1241679-50-4) represents a significant advancement in pharmaceutical chemistry with its unique structural features and diverse applications. The combination of stereochemistry, fluorine substitution, and functional group compatibility makes this compound a versatile tool for drug discovery. As research continues to uncover new therapeutic targets and develop innovative synthetic methodologies, compounds like (CAS No. 1241679-50-4) are poised to play a crucial role in shaping future treatments for various human diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)